PETV · XBRL financial data

PetVivo Holdings financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (PETV's year ends in late March)

In thousands of dollars	Q2 FY24Sep 30, 2023	Q3 FY24Dec 31, 2023	Q4 FY24Mar 31, 2024	Q1 FY25Jun 30, 2024	Q2 FY25Sep 30, 2024	Q3 FY25Dec 31, 2024	Q4 FY25Mar 31, 2025	Q1 FY26Jun 30, 2025	Q2 FY26Sep 30, 2025	Q3 FY26Dec 31, 2025	Q4 FY26Mar 31, 2026	Q1 FY27Jun 30, 2026
Revenue from contracts with customers	207	596	48*	124	201	583	225*	298	303	286	255*	338
Cost of goods and services sold	141	183	(177)*	13	21	61	42*	111	83	141	51*	114
Gross profit	66	413	225*	111	180	522	183*	187	220	145	203*	223
Research and development	240	231	573*	388	465	372	359*	341	261	323	490*	233
General and administrative	1,692	1,283	1,956*	1,233	1,267	1,185	1,138*	1,069	1,237	1,252	776*	967
Total operating expenses	3,011	2,546	2,875*	2,155	2,353	2,280	2,263*	2,031	2,285	2,336	3,165*	1,832
Operating income (loss)	(2,944)	(2,134)	(2,650)*	(2,044)	(2,173)	(1,758)	(2,080)*	(1,844)	(2,065)	(2,191)	(2,962)*	(1,609)
Interest income	—	—	—	—	—	—	—	13	0*	0*	0*	—
Interest expense	—	—	—	3	2	0	6*	122	(111)*	0	1*	5
Other income (expense)	—	—	—	—	—	26	—	—	—	—	—	—
Net income (loss)	(3,661)	(1,750)	(2,651)*	(2,047)	(2,175)	(1,757)	(2,420)*	(2,311)	(3,008)	(2,191)	(2,963)*	(1,614)
Earnings per share, basic USD per share	(0.28)	(0.12)	(0.16)*	(0.11)	(0.11)	(0.09)	(0.11)*	(0.09)	(0.11)	(0.07)	(0.08)*	(0.05)
Earnings per share, diluted USD per share	(0.28)	(0.12)	(0.16)*	(0.11)	(0.11)	(0.09)	(0.11)*	(0.09)	(0.11)	(0.07)	(0.08)*	(0.05)
Weighted average shares, basic thousands of shares	12,988	14,272	16,970*	18,684	20,099	20,633	22,575*	24,303	27,579	33,674	35,106*	37,055
Weighted average shares, diluted thousands of shares	12,988	14,272	16,970*	18,684	20,099	20,633	22,575*	24,303	27,579	33,674	35,106*	37,055

Balance sheet

CSV

Fiscal quarters (PETV's year ends in late March)

In thousands of dollars	Q2 FY24Sep 30, 2023	Q3 FY24Dec 31, 2023	Q4 FY24Mar 31, 2024	Q1 FY25Jun 30, 2024	Q2 FY25Sep 30, 2024	Q3 FY25Dec 31, 2024	Q4 FY25Mar 31, 2025	Q1 FY26Jun 30, 2025	Q2 FY26Sep 30, 2025	Q3 FY26Dec 31, 2025	Q4 FY26Mar 31, 2026	Q1 FY27Jun 30, 2026
Cash and cash equivalents	55	80	87	12	126	29	228	3,304	768	18	201	123
Short-term investments	—	—	—	—	—	—	150	—	—	—	150	—
Accounts receivable	156	519	19	72	134	493	61	26	138	30	101	84
Inventory	434	467	390	384	372	353	324	529	578	605	538	451
Prepaid and other current assets	1,371	427	546	412	614	352	448	392	476	377	270	283
Total current assets	2,016	1,493	1,042	880	1,246	1,227	5,610	4,401	2,110	1,383	1,860	941
Property and equipment, net	665	823	822	806	777	770	767	488	483	464	449	447
Right-of-use asset	1,319	1,254	1,194	1,148	1,102	1,055	962	102	86	71	55	39
Total assets	4,062	3,630	3,115	2,889	3,187	3,112	9,339	6,890	5,258	4,376	3,577	2,669
Accounts payable	912	1,094	821	646	762	1,029	821	744	370	386	547	453
Accrued liabilities	818	242	243	246	396	410	949	846	619	541	454	345
Total current liabilities	1,915	1,662	1,412	1,091	1,858	2,936	4,317	3,117	1,053	988	1,377	1,313
Lease liability, non-current	1,141	1,058	1,004	957	910	863	798	39	23	9	—	—
Total liabilities	3,073	2,735	2,429	2,059	2,778	3,807	5,120	3,160	1,075	997	1,377	1,313
Accumulated deficit	(78,399)	(80,149)	(82,799)	(84,846)	(87,022)	(88,779)	(91,198)	(93,538)	(96,671)	(98,987)	(102,076)	(103,051)
Total stockholders' equity	989	895	686	830	409	(695)	4,219	3,731	4,183	3,379	2,199	1,356
Total liabilities and equity	4,062	3,630	3,115	2,889	3,187	3,112	9,339	6,890	5,258	4,376	3,577	2,669
Common shares outstanding (cover page) thousands of shares	14,468	16,770	19,905	20,005	20,857	22,202	24,389	27,903	33,581	35,017	37,594	37,950

Cash flows

CSV

Fiscal quarters (PETV's year ends in late March)

In thousands of dollars	Q2 FY24Sep 30, 2023	Q3 FY24Dec 31, 2023	Q4 FY24Mar 31, 2024	Q1 FY25Jun 30, 2024	Q2 FY25Sep 30, 2024	Q3 FY25Dec 31, 2024	Q4 FY25Mar 31, 2025	Q1 FY26Jun 30, 2025	Q2 FY26Sep 30, 2025	Q3 FY26Dec 31, 2025	Q4 FY26Mar 31, 2026	Q1 FY27Jun 30, 2026
Net income (loss)	(3,661)	(1,750)	(2,651)*	(2,047)	(2,175)	(1,757)	(2,420)*	(2,311)	(3,008)	(2,191)	(2,963)*	(1,614)
Stock-based compensation	607*	517*	572*	352	349*	316*	90*	133	699*	568*	479*	461
Depreciation and amortization	32*	30*	33*	33	33*	32*	76*	118	124*	135*	135*	—
Net cash from operating activities	(2,442)*	(1,291)*	(1,524)*	(1,530)	(1,600)*	(961)*	(1,230)*	(1,634)	(2,194)*	(1,467)*	(812)*	(966)
Purchases of property and equipment	46*	186*	29*	15	3*	24*	21*	—	—	(5)*	0*	12
Net cash from investing activities	(46)*	(186)*	(29)*	(15)	(3)*	(24)*	(521)*	—	—	5*	0*	(12)
Proceeds from issuing common stock	1,776*	(3,586)*	6,382*	1,323	0*	113*	615*	—	—	—	year only	150
Net cash from financing activities	2,324*	1,502*	1,561*	1,471	1,718*	888*	1,950*	4,710	(348)*	712*	995*	900
Net change in cash	(164)*	25*	7*	(75)	114*	(97)*	199*	3,076	(2,536)*	(750)*	183*	(78)

Compare with peers

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
PetVivo Holdings	123	338	(966)	38.0M	0.1 quarters	Q1 FY27 10-QJun 30, 2026
PAVmed	3,784	33	(2,663)*	8.0M	1.4 quarters	Q2 FY26 10-QJun 30, 2026
Intelligent Bio Solutions	3,992	1,146*	(3,182)*	3.0M	1.3 quarters	Q4 FY26 10-KJun 30, 2026
Envoy Medical	19,679	51	(5,456)*	77.2M	3.6 quarters	Q2 FY26 10-QJun 30, 2026
VASO	38,291	not reported	17,444*	176.0M	—	Q2 FY26 10-QJun 30, 2026
Lyra Therapeutics	15,893	7*	(6,066)*	1.8M	2.6 quarters	Q4 FY25 10-KDec 31, 2025
Nexgel	1,706	3,686	(2,197)*	9.7M	0.8 quarters	Q2 FY26 10-QJun 30, 2026
Biotricity	467	4,277	507	19.9M	—	Q1 FY27 10-QJun 30, 2026
Guided Therapeutics	12	0	(319)*	96.5M	0.0 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.